@entity228 withdrawal after orthotopic liver transplantation (OLT) represents an attractive therapeutic option for ameliorating post-OLT metabolic complications, although several reports suggest @entity1 who undergo transplantation for @entity775 ( @entity775 ) may have a greater incidence of acute and chronic rejection when withdrawn from @entity228 therapy. The aim of this study is to evaluate the success of @entity228 withdrawal in @entity1 with @entity775 after OLT. Twenty-six @entity1 underwent successful OLT for @entity775 . In 21 of these @entity1 , stable maintenance immunosuppression consisted of @entity205 (CSA) and @entity229 (n = 20) or @entity1140 ( @entity11636 ) and @entity229 (n = 1). In this group, a trial of @entity229 withdrawal was initiated when @entity1 were 6 months or more post-OLT, with normal liver function, and receiving an average @entity229 dosage of 10 mg/d. Five additional @entity1 treated with either TAC (n = 4) or CSA (n = 1) plus @entity618 underwent a 14-day taper of @entity229 . Overall, 17 of 25 @entity1 (68%) were successfully withdrawn from @entity288 , with a mean follow-up of 22 months (range, 1 to 34 months). Of the remaining 8 @entity1 , 5 @entity1 received a lower dosage of @entity229 or required @entity229 to control @entity29 . Only 3 @entity1 remained dependent on @entity229 to maintain stable liver allograft function. Withdrawal from 10 to 5 mg of @entity229 (n = 21) resulted in four episodes of @entity134 -responsive and two episodes of @entity134 -resistant rejection in 3 @entity1 , and 18 of 21 @entity1 (86%) were rejection free. Withdrawal from 5 to 0 mg @entity229 (n = 17) resulted in eight episodes of @entity134 -responsive and no episodes of @entity134 -resistant rejection in 4 @entity1 ; 13 of 17 @entity1 (76%) were rejection free. Of the 5 @entity1 in the 14-day @entity229 -taper group, 3 @entity1 had @entity134 -responsive rejection and 1 @entity1 required OKT3. Seventeen of 21 @entity1 (81%) with @entity775 were successfully withdrawn from corticosteroids. It is notable that @entity228 withdrawal was associated with a reduction in serum @entity165 levels, decreased use of antihypertensive agents, and reduced need for insulin or oral hypoglycemic agents. We propose @entity228 withdrawal should be attempted in @entity1 with underlying @entity775 who undergo OLT because most will benefit without significantly jeopardizing the liver allograft.

Successful withdrawal of @entity229 after adult liver transplantation for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid', 'Corticosteroid'] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus'] @entity11636 :: ('CHEBI:53498', 'Chemical') :: ['TAC'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol'] @entity775 :: ('MESH:D019693', 'Disease') :: ['AIH', 'autoimmune hepatitis']
@entity775 :: (MESH:D019693,Disease) :: ['autoimmune hepatitis']
